{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:33:06Z","timestamp":1791898386107,"version":"4.3.4"},"reference-count":117,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-162228"],"award-info":[{"award-number":["PJT-162228"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","award":["V2023-024"],"award-info":[{"award-number":["V2023-024"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017559","name":"The Garron Family Cancer Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006126","name":"Hospital for Sick Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025522","name":"FDC Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025522","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015454","name":"Centre for Applied Genomics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015454","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.celrep.2025.115537","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T13:52:25Z","timestamp":1744379545000},"page":"115537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-8995","authenticated-orcid":false,"given":"Madeline N.","family":"Hayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cohen-Gogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Layeghifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yagnesh","family":"Ladumor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Valencia-Sama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Rajaselvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Shlien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith S.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2025.115537_bib1","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1200\/JCO.21.00278","article-title":"Revised Neuroblastoma Risk Classification System: A Report From the Children\u2019s Oncology Group","volume":"39","author":"Irwin","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.0.CO;2-7","article-title":"The International Neuroblastoma Pathology Classification (the Shimada system)","volume":"86","author":"Shimada","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib3","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","article-title":"Advances in risk classification and treatment strategies for neuroblastoma","volume":"33","author":"Pinto","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib4","first-page":"225","article-title":"Neuroblastoma: Paradigm for precision medicine","volume":"62","author":"Irwin","year":"2015","journal-title":"Pediatr. Clin."},{"key":"10.1016\/j.celrep.2025.115537_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng.2529","article-title":"The genetic landscape of high-risk neuroblastoma","volume":"45","author":"Pugh","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib6","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1056\/NEJMoa0708698","article-title":"Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma","volume":"358","author":"Maris","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115537_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006787","article-title":"Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma","volume":"13","author":"McDaniel","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nature10910","article-title":"Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes","volume":"483","author":"Molenaar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115537_bib9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature09609","article-title":"Integrative genomics identifies LMO1 as a neuroblastoma oncogene","volume":"469","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115537_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ng.2493","article-title":"Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma","volume":"45","author":"Sausen","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ng.374","article-title":"Common variations in BARD1 influence susceptibility to high-risk neuroblastoma","volume":"41","author":"Capasso","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3349","article-title":"Mutational dynamics between primary and relapse neuroblastomas","volume":"47","author":"Schramm","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ng.3333","article-title":"Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations","volume":"47","author":"Eleveld","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","article-title":"ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma","volume":"26","author":"Bresler","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2025.115537_bib15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature07398","article-title":"Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma","volume":"455","author":"Janoueix-Lerosey","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115537_bib16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Moss\u00e9","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115537_bib17","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.28687","article-title":"Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era","volume":"120","author":"Kushner","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib18","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.molonc.2016.07.012","article-title":"Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma","volume":"10","author":"Hallett","year":"2016","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s43018-022-00474-y","article-title":"The clinical utility of genomics in childhood cancer extends beyond targetable mutations","volume":"4","author":"Villani","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s43018-021-00172-1","article-title":"Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors","volume":"2","author":"Fiala","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jnci\/djad183","article-title":"Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival","volume":"116","author":"Kim","year":"2024","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.celrep.2025.115537_bib22","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","article-title":"Germline Mutations in Predisposition Genes in Pediatric Cancer","volume":"373","author":"Zhang","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115537_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115537_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2025.115537_bib25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","article-title":"Tumour lineage shapes BRCA-mediated phenotypes","volume":"571","author":"Jonsson","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115537_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn1382","article-title":"RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition","volume":"8","author":"Nunes","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.celrep.2025.115537_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43134-0","article-title":"A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.115537_bib29","article-title":"EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.115537_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246244","article-title":"EZH2 inhibition decreases neuroblastoma proliferation and in\u00a0vivo tumor growth","volume":"16","author":"Bownes","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2025.115537_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20153700","article-title":"Co-inhibition of the DNA damage response and chk1 enhances apoptosis of neuroblastoma cells","volume":"20","author":"Ando","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.celrep.2025.115537_bib32","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/cncr.34786","article-title":"Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma","volume":"129","author":"Cole","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib33","doi-asserted-by":"crossref","DOI":"10.3892\/or.2023.8603","article-title":"Efficacy of combined targeted therapy with PI3K and CDK4\/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines","volume":"50","author":"Lukoseviciute","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.celrep.2025.115537_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpedsurg.2013.09.051","article-title":"Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma","volume":"49","author":"Romain","year":"2014","journal-title":"J.\u00a0Pediatr. Surg."},{"key":"10.1016\/j.celrep.2025.115537_bib35","article-title":"Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells","volume":"20","author":"Yang","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.celrep.2025.115537_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115033","article-title":"Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma","volume":"247","author":"Rishfi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.celrep.2025.115537_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315242121","article-title":"ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition","volume":"121","author":"Boren\u00e4s","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.115537_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13046-020-01582-2","article-title":"Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma","volume":"39","author":"George","year":"2020","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2025.115537_bib39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s43018-020-00171-8","article-title":"Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma","volume":"2","author":"Roeschert","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib40","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1038\/s41467-021-27057-2","article-title":"ATR inhibition enables complete tumour regression in ALK-driven NB mouse models","volume":"12","author":"Szydzik","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.115537_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djx062","article-title":"Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor","volume":"109","author":"Takagi","year":"2017","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.celrep.2025.115537_bib42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fonc.2020.00371","article-title":"Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma","volume":"10","author":"Southgate","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib43","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/cancers12051095","article-title":"ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms","volume":"12","author":"Southgate","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.celrep.2025.115537_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102971","article-title":"Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma","volume":"59","author":"George","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.celrep.2025.115537_bib45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/jnci\/djad182","article-title":"BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma","volume":"116","author":"Randall","year":"2024","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.celrep.2025.115537_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJMc2403316","article-title":"Response to PARP Inhibition in BARD1 -Mutated Refractory Neuroblastoma","volume":"391","author":"Cupit-Link","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115537_bib47","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ccr.2012.02.010","article-title":"Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis","volume":"21","author":"Zhu","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2025.115537_bib48","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2017.08.002","article-title":"LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis","volume":"32","author":"Zhu","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2025.115537_bib49","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1016\/j.celrep.2017.02.065","article-title":"Critical Role for GAB2 in Neuroblastoma Pathogenesis Through the Promotion of SHP2\/MYCN Cooperation","volume":"18","author":"Zhang","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2025.115537_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/children5090119","article-title":"Genetic predisposition to neuroblastoma","volume":"5","author":"Barr","year":"2018","journal-title":"Children"},{"key":"10.1016\/j.celrep.2025.115537_bib51","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-020-18987-4","article-title":"Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations","volume":"11","author":"Brady","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.115537_bib52","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/children8060456","article-title":"Molecular genetics in neuroblastoma prognosis","volume":"8","author":"Lerone","year":"2021","journal-title":"Children"},{"key":"10.1016\/j.celrep.2025.115537_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/pbc.24697","article-title":"Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors","volume":"61","author":"Norris","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib54","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37202","article-title":"Tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish","volume":"7","author":"Ignatius","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.celrep.2025.115537_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz3440","article-title":"ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression","volume":"6","author":"Shi","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.celrep.2025.115537_bib56","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1078-0432.CCR-09-1865","article-title":"High frequency of p53\/MDM2\/p14ARF pathway abnormalities in relapsed neuroblastoma","volume":"16","author":"Carr-Wilkinson","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2025.115537_bib57","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1158\/0008-5472.CAN-05-2623","article-title":"Increased frequency of aberrations in the p53\/MDM2\/p14ARF pathway in neuroblastoma cell lines established at relapse","volume":"66","author":"Carr","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2025.115537_bib58","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1038\/sj.onc.1209871","article-title":"Mouse models of BRCA1 and BRCA2 deficiency: Past lessons, current understanding and future prospects","volume":"25","author":"Evers","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2025.115537_bib59","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/cdd.2009.138","article-title":"Escape from p53-mediated tumor surveillance in neuroblastoma: Switching off the p14ARF-MDM2-p53 axis","volume":"16","author":"Van Maerken","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.celrep.2025.115537_bib60","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/0008-5472.CAN-09-2598","article-title":"p53 is a direct transcriptional target of MYCN in neuroblastoma","volume":"70","author":"Chen","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2025.115537_bib61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3835(03)00103-4","article-title":"The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification","volume":"197","author":"Hogarty","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.celrep.2025.115537_bib62","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/biomedicines10020392","article-title":"Loss of atm in Zebrafish as a Model of Ataxia\u2013Telangiectasia Syndrome","volume":"10","author":"Chen","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.celrep.2025.115537_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007821","article-title":"Multiplexed CRISPR\/Cas9-mediated knockout of 19 Fanconi anemia pathway genes in zebrafish revealed their roles in growth, sexual development and fertility","volume":"14","author":"Ramanagoudr-Bhojappa","year":"2018","journal-title":"PLoS Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pgen.1001034","article-title":"Sex reversal in zebrafish fancl mutants is caused by Tp53-mediated germ cell apoptosis","volume":"6","author":"Rodr\u00edguez-Mar\u00ed","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001357","article-title":"Roles of brca2 (fancd1) in oocyte nuclear architecture, gametogenesis, gonad tumors, and genome stability in zebrafish","volume":"7","author":"Rodr\u00edguez-Mar\u00ed","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib66","doi-asserted-by":"crossref","first-page":"19350","DOI":"10.1073\/pnas.1011630107","article-title":"Brca2 in zebrafish ovarian development, spermatogenesis, and tumorigenesis","volume":"107","author":"Shive","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.115537_bib67","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41598-022-04878-9","article-title":"Brca2-Mutant Zebrafish Exhibit Context- and Tissue-Dependent Alterations in Cell Phenotypes and Response To Injury","volume":"12","author":"Kouprianov","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2025.115537_bib68","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1158\/0008-5472.CAN-20-1890","article-title":"GAS7 deficiency promotes metastasis in MYCN-driven neuroblastoma","volume":"81","author":"Dong","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2025.115537_bib69","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2025.115537_bib70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib71","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115537_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41698-022-00291-7","article-title":"PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer","volume":"6","author":"Dillon","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib73","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115537_bib74","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in\u00a0vitro and in\u00a0vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2025.115537_bib75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.celrep.2025.115537_bib76","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1084\/jem.20160378","article-title":"Single-cell imaging of normal and malignant cell engraftment into optically clear prkdc-null scid zebrafish","volume":"213","author":"Moore","year":"2016","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.celrep.2025.115537_bib77","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.cell.2019.04.004","article-title":"Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish","volume":"177","author":"Yan","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2025.115537_bib78","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.18632\/oncotarget.27329","article-title":"MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma","volume":"11","author":"King","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2025.115537_bib79","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.115537_bib80","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.stem.2018.02.002","article-title":"Vangl2\/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma","volume":"22","author":"Hayes","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.celrep.2025.115537_bib81","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.celrep.2017.05.061","article-title":"The NOTCH1\/SNAIL1\/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma","volume":"19","author":"Ignatius","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2025.115537_bib82","article-title":"Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2025.115537_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-45571-8","article-title":"CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model","volume":"9","author":"Swadi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2025.115537_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-015-0224-y","article-title":"Inhibition of CDK4\/6 as a novel therapeutic option for neuroblastoma","volume":"15","author":"Rihani","year":"2015","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.celrep.2025.115537_bib85","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1158\/1078-0432.CCR-16-1114","article-title":"Dual ALK and CDK4\/6 inhibition demonstrates synergy against neuroblastoma","volume":"23","author":"Wood","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2025.115537_bib86","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.devcel.2023.08.028","article-title":"Palbociclib releases the latent differentiation capacity of neuroblastoma cells","volume":"58","author":"Ferguson","year":"2023","journal-title":"Dev. Cell"},{"key":"10.1016\/j.celrep.2025.115537_bib87","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13024-021-00482-z","article-title":"The TGF\u03b2\/Notch axis facilitates M\u00fcller cell-to-epithelial transition to ultimately form a chronic glial scar","volume":"16","author":"Conedera","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.celrep.2025.115537_bib88","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/nar\/gkae031","article-title":"DNA hypomethylation activates Cdk4\/6 and Atr to induce DNA replication and cell cycle arrest to constrain liver outgrowth in zebrafish","volume":"52","author":"Madakashira","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2025.115537_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246215","article-title":"Increased replication stress determines ATR inhibitor sensitivity in neuroblastoma cells","volume":"13","author":"King","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.celrep.2025.115537_bib90","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2025.115537_bib91","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.115537_bib92","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","article-title":"Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK\/15\/010)","volume":"29","author":"Ring","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2025.115537_bib93","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1200\/JCO.2021.39.15_suppl.5516","article-title":"Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer","volume":"39","author":"Wethington","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib94","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115537_bib95","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.115537_bib96","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","article-title":"Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer","volume":"26","author":"Wong","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2025.115537_bib97","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.115537_bib98","article-title":"Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.celrep.2025.115537_bib99","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.celrep.2025.115537_bib100","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"A phase I\u2013II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2-mutated ovarian carcinoma or other solid tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2025.115537_bib101","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2025.115537_bib102","doi-asserted-by":"crossref","first-page":"10047","DOI":"10.1200\/JCO.2019.37.15_suppl.10047","article-title":"AcS\u00e9-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents\u2013Arm D: Olaparib and irinotecan","volume":"37","author":"Gatz","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib103","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.21.02838","article-title":"Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients with Refractory Cancers in the National Cancer Institute-Children\u2019s Oncology Group Pediatric MATCH Trial","volume":"40","author":"Parsons","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib104","unstructured":"St. Jude Children's Research Hospital (2021). NCT04901702: Study of\u00a0Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04901702."},{"key":"10.1016\/j.celrep.2025.115537_bib105","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/jnci\/djac151","article-title":"Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer","volume":"114","author":"Kratz","year":"2022","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.celrep.2025.115537_bib106","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1470-2045(18)30242-0","article-title":"Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort","volume":"19","author":"Waszak","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib107","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jnci\/djaa204","article-title":"Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children\u2019s Oncology Group","volume":"113","author":"Li","year":"2021","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.celrep.2025.115537_bib108","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamaoncol.2020.0197","article-title":"Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma","volume":"6","author":"Mirabello","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.celrep.2025.115537_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pgen.1009231","article-title":"Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high frequency of cancer prone syndromes","volume":"16","author":"Byrjalsen","year":"2020","journal-title":"PLoS Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28047","article-title":"Estimated number of adult survivors of childhood cancer in United States with cancer-predisposing germline variants","volume":"67","author":"Wilson","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.celrep.2025.115537_bib111","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12864-020-6635-8","article-title":"Tracy: Basecalling, alignment, assembly and deconvolution of sanger chromatogram trace files","volume":"21","author":"Rausch","year":"2020","journal-title":"BMC Genom."},{"key":"10.1016\/j.celrep.2025.115537_bib112","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl Variant Effect Predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.celrep.2025.115537_bib113","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","article-title":"Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications","volume":"32","author":"Chen","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2025.115537_bib114","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.115537_bib115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2025.115537_bib116","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2025.115537_bib117","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725003080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725003080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:24:36Z","timestamp":1768339476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124725003080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2211124725003080"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2025.115537","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.09.612065","asserted-by":"object"}]},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2025.115537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115537"}}